Navigation Links
Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
Date:2/23/2011

usion of CD34+ cells. The study is expected to enroll a total of 74 patients at eight leading U.S. medical centers. For more information, please visit http://clinicaltrials.gov/ct2/show/NCT01121120?term=tarix&rank=2.

TXA127 will also be evaluated in two clinical trials in cord blood transplantation. One conducted at M D Anderson will involve adult patients, while the other at Duke University, will enroll pediatric patients.

About Tarix Pharmaceuticals

Tarix Pharmaceuticals is a clinical stage biopharmaceutical company developing peptide drugs to address significant unmet medical needs. The Company's lead product, TXA127, is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7). TXA127 is currently in a Phase II clinical trial for the treatment and prevention of thrombocytopenia (reduced platelet count) associated with cancer chemotherapy, and a Phase II trial for peripheral blood stem cell engraftment. Tarix is preparing additional clinical trials with TXA127 in acute respiratory distress syndrome (ARDS), cord blood stem cell engraftment, and myelodysplastic syndrome (MDS). TXA127 is also being developed, under grants from the US government, as a treatment for radiation exposure.

Tarix's second product, PanCyte, is a synthetic, long-acting analogue of Angiotensin (1-7). PanCyte is in pre-clinical development focused on chemotherapy-induced thrombocytopenia and neutropenia, as well as combination treatment with low dose erythropoietin in chemotherapy-induced anemia.


'/>"/>
SOURCE Tarix Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk
2. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
3. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
4. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
5. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
6. Onyx Pharmaceuticals Reports Full Year and Fourth Quarter 2010 Financial Results
7. Avanir Pharmaceuticals to Present at Three Conferences in March
8. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
9. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
10. Isis Pharmaceuticals to Present at the 2011 Citi Global Healthcare Conference
11. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  The departments of Drug and Alcohol ... Gaudenzia Concept 90 to raise awareness for International Overdose ... Pennsylvania and help more Pennsylvanians ... recovery through the Building Bridges to Recovery ... every day to a disease that is fully treatable, ...
(Date:8/31/2015)... Mich. , Aug. 31, 2015  Diplomat Pharmacy, Inc. ... has announced that Phil Hagerman , Chairman & CEO, ... upcoming investor conferences. Mr. Hagerman and Mr. ... Healthcare Conference in Boston on Wednesday, ... Hagerman and Mr. Whelan are also scheduled to participate in ...
(Date:8/31/2015)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... has completed enrollment of the additional subjects, as ... this year, into the company,s Phase 2 study ... regulator (IDR) and is being evaluated as a ...
Breaking Medicine Technology:Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
... 8, 2011 Elsevier Business Intelligence , ... conferences, is hosting Windhover,s 21 st Pharmaceutical Strategic ... in New York, NY. PSA is the only ... a diverse mix of pharma,s top talent. It,s an opportunity ...
... Medical, a leading manufacturer of integrated medical imaging display and ... year, Carrot Medical achieved significant growth in sales and an ... of 2011 with record second quarter sales, Carrot surpassed its ... company is now well positioned for the third straight year ...
Cached Medicine Technology:Biopharma Leaders Discuss Pharma's Future at Pharmaceutical Strategic Alliances in New York 2Biopharma Leaders Discuss Pharma's Future at Pharmaceutical Strategic Alliances in New York 3Carrot Medical Positioned for Third Straight Year of Triple Digit Growth 2
(Date:8/31/2015)... ... September 01, 2015 , ... Spinal fusion surgery – ... required a long, arduous recovery. However, today’s minimally invasive fusions achieve similar results ... and minimal muscle damage. These advantages of minimally invasive surgery redeem the procedure’s ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dental clinicians from ... of Health Sciences to learn more about its integrated approach to diabetes care. ... and Institute of Cellular Medicine at Newcastle University, and Susan Bissett, National Institute ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... registration for the company’s second Introduction to Hyperbaric Medicine Course. The next UHMS ... aboard the Queen Mary Hotel in Long Beach, CA. The meeting is open ...
(Date:8/31/2015)... ... August 31, 2015 , ... CareSource, a nonprofit Ohio-based health ... this capacity, Michael will provide strategic leadership for CareSource’s marketing, branding, corporate communications ... that have contributed to the company’s rapid growth. As the CareSource business model ...
(Date:8/31/2015)... ... August 31, 2015 , ... In an article ... Plastic and Reconstructive Surgery Global Open Journal that discusses the future of 3-D printing ... how, in the future, customized implants, prosthetics, and other 3-D printed tools could be ...
Breaking Medicine News(10 mins):Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3
... ANGELES, April 9 The Los Angeles ... children hospitalized for,cancer and other serious illnesses, ... a half block from its original Fountain ... low cost, often free, lodging to,75-families per ...
... years off biological age , , WEDNESDAY, April 9 (HealthDay News) ... aging by up to 12 years, a new analysis shows. ... body,s oxygen consumption and its use in generating energy (metabolism). ... middle age, decreasing about 5 ml/ (kg. min) every decade, ...
... OCEANSIDE, Calif., April 9 Healthcare,workers at Tri-City ... from the State Mediation & Conciliation Service,confirmed that ... majority of union authorization cards., TCMC caregivers ... West,and join thousands of other healthcare workers who ...
... often influenced by patients, with patient experience using ... the Management Insights feature in the current issue ... Institute for Operations Research and the Management Sciences ... who market pharmaceuticals. , Management Insights, a regular ...
... HARRISBURG, Pa., April 9 Survivors of sexual,abuse ... Capitol Rotunda,Wednesday in an effort to bring awareness ... http://www.newscom.com/cgi-bin/prnh/20080409/DC19028 ), The Support Our ... Rape., State funding for victim services remained ...
... similar results , , WEDNESDAY, April 9 (HealthDay News) -- Carotid ... the brain to prevent a stroke -- is as effective ... called endarterectomy, a study shows. , But endarterectomy -- the ... be the treatment of choice for the 70 percent to ...
Cached Medicine News:Health News:Los Angeles Ronald McDonald House Doubles Lodging Capacity for Families of Hospitalized Children 2Health News:Los Angeles Ronald McDonald House Doubles Lodging Capacity for Families of Hospitalized Children 3Health News:Aerobic Exercise Keeps You Young 2Health News:North County Caregivers Join United Healthcare Workers 2Health News:Forecasting MDs' prescriptions' choice? Ask their patients, says Management Insights study 2Health News:Forecasting MDs' prescriptions' choice? Ask their patients, says Management Insights study 3Health News:Pennsylvania Legislators Attend Victim Services Rally 2Health News:Stenting as Good as Surgery for Stroke Prevention 2
LUMIGAN® is a powerful eye drop medication for lowering IOP. IOP is short for intraocular pressure or eye pressure. LUMIGAN® is the first in a new class of medication....
... New REFRESH LIQUIGEL® Lubricant Eye Drops ... with the convenience of a liquid ... protection. Its extra-strength CMC formula provides ... comfort. And with the PURITE® preservative, ...
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
... solution is an anti-infective prescription ... may instruct you to use ... infection caused by bacteria. Bacterial ... the 2 types of eye ...
Medicine Products: